Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FRK | P42685 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8950122 | 0.80 | TDP1 (0.42) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL8950095 | 0.77 | PIK3CA (0.38) | PIK3CAADRA1DADRA1A | |
| SCHEMBL8950089 | 0.75 | PIK3CA (0.41) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL8950307 | 0.72 | ADRA1D (0.41) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL8950502 | 0.72 | ADRA1D (0.39) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL8950449 | 0.71 | PIK3CD (0.48) | PIK3CACYP2D6PIK3CDPIK3CGPIK3CB | |
| SCHEMBL4505142 | 0.71 | CDK2 (0.49) | MAPK9CSNK1A1GSK3B | |
| SCHEMBL8950312 | 0.70 | PIK3CA (0.43) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL28368621 | 0.70 | PIK3CA (0.43) | PIK3CAADRA1DADRA1APIK3CDPIK3CG | |
| SCHEMBL8950490 | 0.69 | ADRA1D (0.36) | PIK3CAADRA1DADRA1APIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | PIK3CA 881/4885ADRA1D 2746/4885ADRA1A 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.